Sofosbuvir CAS 1190307-88-0 Purity ≥99.0% (HPLC)

Short Description:

Name: Sofosbuvir

CAS: 1190307-88-0

Appearance: White to Off-White Crystalline Powder

Purity: ≥99.0% (HPLC) 

Sofosbuvir in the treatment of Hepatitis C Virus (HCV)

API High Quality, Commercial Production

Contact: Dr. Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Sofosbuvir Related Intermediates:

1190307-88-0 - Chemical Properties:

Name Sofosbuvir
Synonyms GS-7977; PSI-7977
CAS Number 1190307-88-0
Stock Status In Stock, Production Scale Up to Hundreds of Kilograms
Molecular Formula C22H29FN3O9P
Molecular Weight 529.45
Melting Point 120.0~125.0℃
Density 1.41
Solubility Soluble in DMF, DMSO, Ethanol
Shipping Condition Under Ambient Temperature
COA & MSDS Available
Origin Shanghai, China
Shelf Life  36 Months if Stored Properly
Brand Ruifu Chemical

1190307-88-0 - Specifications:

Item Specifications
Appearance White to Off-White Crystalline Powder
Identification HPLC; RT
Purity / Analysis Method ≥99.0% (HPLC)
E.E ≥99.0%
Loss on Drying ≤1.0% 
Residue on Ignition ≤0.20% 
Single Impurity ≤0.50% 
Total Impurities  ≤1.0% 
Heavy Metals ≤20ppm
Residual Solvents Meet the requirements of specifications
Methanol ≤1500ppm
TBME ≤2500ppm
Dichloromethane ≤720ppm
Tetrahydrofuran ≤720ppm
Toluene ≤60ppm
Test Standard Enterprise Standard
Usage Sofosbuvir (CAS: 1190307-88-0) in the treatment of Hepatitis C Virus (HCV)

Package & Storage:

Package: Bottle, Aluminum foil bag, 25kg/Drum, or according to customer's requirement 

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture 

Advantages:

1

FAQ:

www.ruifuchem.com

1190307-88-0 - Application:

Sofosbuvir (CAS: 1190307-88-0) (formally labeled as PSI-797, GS-7977) is a phosphoramidate prodrug and nucleotide polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection. It is recommended to be used in combination with other drugs (such as velpatasvir) for the first-line treatment for HCV genotypes 1, 2, 3, 4, 5, and 6. It takes effect through acting as a nucleotide analog inhibitor, being capable of specially inhibiting the HCV NS5B (non-structural protein 5B) RNA-dependent RNA polymerase.  

  • Write your message here and send it to us